Mani S, Barry M, Concato J
Department of Internal Medicine, Yale University School of Medicine, New Haven, Conn.
Arch Intern Med. 1993 Nov 8;153(21):2500-1.
Drug-induced agranulocytosis in the outpatient setting is a rare but potentially fatal adverse effect of many classes of medications. Five patients with this disorder presented to Yale-New Haven (Conn) Hospital during 1990 through 1992. Three patients treated with granulocyte-colony stimulating factor and two patients treated with routine care were studied for relevant clinical outcomes. Treatment with granulocyte-colony stimulating factor was associated with a shorter duration of neutropenia and a decreased length of hospital stay, consistent with recent case reports. Despite the high cost of the drug, treatment with granulocyte-colony stimulating factor was found to be cost-effective for patients with uncomplicated drug-induced agranulocytosis.
门诊环境下药物诱导的粒细胞缺乏症是许多类药物罕见但可能致命的不良反应。1990年至1992年期间，有5例患有这种疾病的患者前往康涅狄格州耶鲁-纽黑文医院就诊。对3例接受粒细胞集落刺激因子治疗的患者和2例接受常规治疗的患者的相关临床结局进行了研究。与最近的病例报告一致，粒细胞集落刺激因子治疗与中性粒细胞减少持续时间缩短和住院时间缩短相关。尽管该药物成本高昂，但对于无并发症的药物诱导的粒细胞缺乏症患者，使用粒细胞集落刺激因子治疗被认为具有成本效益。
